Insider Selling: Guardian Pharmacy Services (NYSE:GRDN) Director Sells 3,570,677 Shares of Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director William Bindley sold 3,570,677 shares of the company’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $105,977,693.36. Following the completion of the sale, the director owned 4,469,316 shares of the company’s stock, valued at approximately $132,649,298.88. The trade was a 44.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Guardian Pharmacy Services Trading Up 0.9%

Shares of NYSE:GRDN opened at $37.58 on Wednesday. Guardian Pharmacy Services, Inc. has a 12-month low of $19.17 and a 12-month high of $38.12. The company has a market cap of $2.38 billion, a PE ratio of 48.81 and a beta of 0.86. The stock has a 50 day moving average of $32.49 and a 200 day moving average of $29.83.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings data on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.10. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The firm had revenue of $397.62 million during the quarter, compared to analysts’ expectations of $390.04 million. Guardian Pharmacy Services’s revenue for the quarter was up 17.4% on a year-over-year basis. Equities research analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on GRDN shares. Truist Financial upped their target price on shares of Guardian Pharmacy Services from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. Raymond James Financial reiterated an “outperform” rating and issued a $40.00 price target on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Weiss Ratings restated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Oppenheimer lifted their target price on Guardian Pharmacy Services from $35.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Finally, UBS Group reiterated a “buy” rating on shares of Guardian Pharmacy Services in a research report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $38.00.

Hedge Funds Weigh In On Guardian Pharmacy Services

Institutional investors have recently bought and sold shares of the business. Brown Advisory Inc. grew its stake in shares of Guardian Pharmacy Services by 5.0% during the second quarter. Brown Advisory Inc. now owns 1,682,476 shares of the company’s stock valued at $35,854,000 after buying an additional 79,652 shares during the last quarter. Valiant Capital Management L.P. raised its holdings in shares of Guardian Pharmacy Services by 15.8% in the fourth quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock worth $37,085,000 after buying an additional 167,741 shares during the period. Wellington Management Group LLP lifted its stake in shares of Guardian Pharmacy Services by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 1,143,729 shares of the company’s stock worth $30,000,000 after acquiring an additional 36,072 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Guardian Pharmacy Services by 8.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,056,240 shares of the company’s stock worth $27,705,000 after acquiring an additional 80,033 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Guardian Pharmacy Services by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,055,102 shares of the company’s stock valued at $27,675,000 after acquiring an additional 88,296 shares during the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.